Quote | Purple Biotech Ltd ADR (Sponsored) Level 3 (NASDAQ:PPBT)
Last: | $0.3626 |
---|---|
Change Percent: | -1.95% |
Open: | $0.3698 |
Close: | $0.369799 |
High: | $0.3698 |
Low: | $0.356 |
Volume: | 104,569 |
Last Trade Date Time: | 07/03/2024 03:00:00 am |
News | Purple Biotech Ltd ADR (Sponsored) Level 3 (NASDAQ:PPBT)
REHOVOT, Israel, July 02, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (“Purple Biotech” or “the Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance, today anno...
REHOVOT, Israel, July 01, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (“Purple Biotech” or “the Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance, today announced ...
Message Board Posts | Purple Biotech Ltd ADR (Sponsored) Level 3 (NASDAQ:PPBT)
Subject | By | Source | When |
---|---|---|---|
whytestocks: $KTOV News Article - New Mechanism of Action Data for NT219 Presented at Epigenetics an | whytestocks | investorshangout | 10/16/2020 4:35:45 PM |
whytestocks: $KTOV News Article - Kitov Pharma Receives Notice of Intention to Grant Two Patents in | whytestocks | investorshangout | 09/04/2020 7:30:46 PM |
znewcar1: KTOV 837% v1,5M c4.77 f17,2M RS | znewcar1 | investorshangout | 08/21/2020 8:07:55 PM |
whytestocks: $KTOV News Article - Kitov Announces Initiation of Phase 1/2 Clinical Trial of NT219 in | whytestocks | investorshangout | 07/09/2020 12:15:48 PM |
znewcar1: KTOV 46% v219M c1.26 f118M H1.4 S1.07 | znewcar1 | investorshangout | 06/25/2020 9:39:00 PM |
News, Short Squeeze, Breakout and More Instantly...
Purple Biotech Ltd ADR (Sponsored) Level 3 Company Name:
PPBT Stock Symbol:
NASDAQ Market:
Purple Biotech Ltd ADR (Sponsored) Level 3 Website:
REHOVOT, Israel, July 02, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (“Purple Biotech” or “the Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance, today anno...
REHOVOT, Israel, July 01, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (“Purple Biotech” or “the Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance, today announced ...
New data suggests that b aseline serum myeloperoxidase (MPO) levels below the threshold may predict overall survival (OS) improvement when comparing the CM24+nivolumab+Nal-IRI/5FU/LV vs. Nal-IRI/5FU/LV arms Data reported at the 2024 ASCO annual meeting demonstrated reduced risk of death...